Background/Aims@#
Teicoplanin can be used as an alternative to
vancomycin when treating
beta-lactam-resistant
gram-positive bacterial infections. Both
vancomycin and
teicoplanin are associated with relatively high rates of
adverse drug reactions (ADRs), including
hypersensitivity reactions. There is limited data on
teicoplanin-
vancomycin cross-reactivity. This study examined the
incidence of
teicoplanin ADRs and
risk factors for cross-reactivity between
vancomycin and
teicoplanin. @*
Methods@#We analyzed the
incidence of
teicoplanin ADRs in a
retrospective study of 304 newly
teicoplanin-exposed, immunocompetent, hospitalized
patients at a single Korean Medical Center between January 1, 2006 and December 31, 2015. @*Results@#Among 304
patients, 238 (78.3%) experienced
vancomycin-associated ADRs prior to their
teicoplanin exposure and 58 (19.1%) experienced
teicoplanin- associated ADRs, which were mostly
hypersensitivity reactions without
acute kidney injury. The
incidence of
teicoplanin ADRs was higher in
patients who previously experienced
vancomycin-related ADRs (23.1% vs. 5.3%, p < 0.001).
History of
drug allergy was a statistically significant
risk factor of
teicoplanin ADRs. The
incidence of
teicoplanin ADRs significantly increased in
patients with multiple organ involvement in
vancomycin hypersensitivity reactions. @*Conclusions@#
Teicoplanin should be administered with caution and clinicians must consider the
risk factors of cross-reaction when prescribing
teicoplanin to individuals with a
history of
vancomycin hypersensitivity.